BOLTHealthcare · BiotechnologyBOLT Stock Forecast: Bolt Biotherapeutics, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Bolt Biotherapeutics, Inc. hold a median 12-month price target of $41 — +930.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
BOLT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Bolt Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (100): Sales and profits are climbing, and climbing faster than before.
Momentum (17): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Bolt Biotherapeutics, Inc. — and when they’d sell — is the membership.
BOLT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BOLT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +930.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 May 2026 | Rodman & Renshaw | Initiates | Buy | $22 |
| 28 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 13 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Oct 2025 | HC Wainwright & Co. | Assumes | Buy | $7.00 |
| 15 Aug 2025 | Lake Street | Maintains | Buy | — |
| 20 May 2025 | Lake Street | Initiates | Buy | — |
| 13 May 2025 | Stifel | Maintains | Hold | — |
| 25 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 25 Mar 2025 | Stifel | Maintains | Hold | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 15 May 2024 | Guggenheim | Downgrade | Neutral | — |
| 15 May 2024 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 15 May 2024 | Jones Trading | Downgrade | Hold | — |
| 15 May 2024 | Leerink Partners | Downgrade | Market Perform | — |
| 15 May 2024 | Stifel | Downgrade | Hold | — |
| 22 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BOLT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Bolt Biotherapeutics, Inc. (BOLT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.2×
- Price / sales
- 1.2×
- Price / book
- 0.4×
- EV / EBITDA
- −0.2×
Cheaper than 78% of US stocks
Cheaper than 66% of US stocks
Cheaper than 86% of US stocks
Cheaper than 63% of US stocks
- Revenue growth (YoY)
- −97.9%
- Earnings growth (YoY)
- −97.9%
- Gross margin
- —
- Operating margin
- −29234.6%
- Net margin
- 0.0%
Higher than 2% of US stocks
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
- Return on equity
- −88.8%
- Return on assets
- −28.1%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BOLT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BOLT appears on the weeks it earns a place.
Frequently asked questions about BOLT stock
What is the BOLT stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Bolt Biotherapeutics, Inc. have a median 12-month price target of $41, with estimates ranging from $7 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BOLT stock a buy right now?
Of the 4 analysts covering Bolt Biotherapeutics, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bolt Biotherapeutics, Inc. 75 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BOLT?
As at 1 Aug 2026, Bolt Biotherapeutics, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).
Will BOLT stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +930.2% from the last close, and Ticker Nerd's factor model ranks Bolt Biotherapeutics, Inc. 75 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BOLT stock forecast for 2030?
No analyst covering Bolt Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BOLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $75 over the next 12 months.
How has BOLT stock performed over the past year?
Bolt Biotherapeutics, Inc. returned -28.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Bolt Biotherapeutics, Inc. do?
Bolt Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment. The company harnesses the immune system through its proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, which combines tumor-targeting antibodies with immune-stimulating linker-payloads to activate both innate and adaptive immune responses against tumors. Key pipeline candidates include BDC-1001, targeting HER2-positive solid tumors such as breast, colorectal, endometrial, and gastroesophageal cancers; BDC-3042, an agonist antibody targeting Dectin-2 on tumor-associated macrophages for tumors like head and neck, non-small cell lung, ovarian, and triple-negative breast cancers; and BDC-4182, a next-generation ISAC targeting claudin 18.2, overexpressed in gastric, gastroesophageal junction, and pancreatic cancers. Bolt Biotherapeutics Inc. maintains collaborations with partners including Toray Industries, Genmab, and Innovent Biologics to advance its ISAC technologies. Incorporated in 2015 and headquartered in Redwood City, California, the company operates in the biotechnology sector of healthcare, emphasizing myeloid biology and immuno-oncology drug development.
CEO Mr. William P. Quinn · 52 employees · United States · https://www.boltbio.com